Lonza partners with biotech firm HaemaLogiX on multiple myeloma drug candidate
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China